GB9725764D0 - HLA-E binding - Google Patents

HLA-E binding

Info

Publication number
GB9725764D0
GB9725764D0 GBGB9725764.6A GB9725764A GB9725764D0 GB 9725764 D0 GB9725764 D0 GB 9725764D0 GB 9725764 A GB9725764 A GB 9725764A GB 9725764 D0 GB9725764 D0 GB 9725764D0
Authority
GB
United Kingdom
Prior art keywords
cells
hla
binding
nkg2
inactivation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB9725764.6A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford University Innovation Ltd
Original Assignee
Oxford University Innovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford University Innovation Ltd filed Critical Oxford University Innovation Ltd
Priority to GBGB9725764.6A priority Critical patent/GB9725764D0/en
Publication of GB9725764D0 publication Critical patent/GB9725764D0/en
Priority to DE69841020T priority patent/DE69841020D1/de
Priority to PCT/GB1998/003686 priority patent/WO1999028748A2/en
Priority to EP98959027A priority patent/EP1036327B1/en
Priority to EP09165917A priority patent/EP2144065A1/en
Priority to AT98959027T priority patent/ATE438096T1/de
Priority to JP2000523554A priority patent/JP4336451B2/ja
Priority to US09/555,555 priority patent/US7410767B1/en
Priority to US12/109,990 priority patent/US20080274475A1/en
Priority to JP2008314107A priority patent/JP4437160B2/ja
Priority to JP2009191564A priority patent/JP5268828B2/ja
Priority to JP2013006244A priority patent/JP2013081478A/ja
Priority to US14/683,835 priority patent/US20150361180A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70539—MHC-molecules, e.g. HLA-molecules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/7056—Selectin superfamily, e.g. LAM-1, GlyCAM, ELAM-1, PADGEM

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pregnancy & Childbirth (AREA)
GBGB9725764.6A 1997-12-04 1997-12-04 HLA-E binding Ceased GB9725764D0 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
GBGB9725764.6A GB9725764D0 (en) 1997-12-04 1997-12-04 HLA-E binding
US09/555,555 US7410767B1 (en) 1997-12-04 1998-12-04 HLA-E binding
JP2000523554A JP4336451B2 (ja) 1997-12-04 1998-12-04 Ｈｌａ−ｅ結合
PCT/GB1998/003686 WO1999028748A2 (en) 1997-12-04 1998-12-04 Hla-e binding
EP98959027A EP1036327B1 (en) 1997-12-04 1998-12-04 HLA-E binding to CD94/NKG2+ cells
EP09165917A EP2144065A1 (en) 1997-12-04 1998-12-04 HLA-E Binding
AT98959027T ATE438096T1 (de) 1997-12-04 1998-12-04 Hla-e bindung zu cd94/nkg2+ zellen
DE69841020T DE69841020D1 (de) 1997-12-04 1998-12-04 HLA-E Bindung zu CD94/NKG2+ Zellen
US12/109,990 US20080274475A1 (en) 1997-12-04 2008-04-25 Hla-e binding
JP2008314107A JP4437160B2 (ja) 1997-12-04 2008-12-10 Ｈｌａ−ｅ結合
JP2009191564A JP5268828B2 (ja) 1997-12-04 2009-08-21 Ｈｌａ−ｅ結合
JP2013006244A JP2013081478A (ja) 1997-12-04 2013-01-17 Ｈｌａ−ｅ結合
US14/683,835 US20150361180A1 (en) 1997-12-04 2015-04-10 Hla-e binding

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9725764.6A GB9725764D0 (en) 1997-12-04 1997-12-04 HLA-E binding

Publications (1)

Publication Number Publication Date
GB9725764D0 true GB9725764D0 (en) 1998-02-04

Family

ID=10823165

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB9725764.6A Ceased GB9725764D0 (en) 1997-12-04 1997-12-04 HLA-E binding

Country Status (7)

Country Link
US (3) US7410767B1 (https=)
EP (2) EP1036327B1 (https=)
JP (4) JP4336451B2 (https=)
AT (1) ATE438096T1 (https=)
DE (1) DE69841020D1 (https=)
GB (1) GB9725764D0 (https=)
WO (1) WO1999028748A2 (https=)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9725764D0 (en) * 1997-12-04 1998-02-04 Isis Innovation HLA-E binding
KR20040041575A (ko) * 2001-07-31 2004-05-17 칼 페터 쇠더스트룀 면역반응의 모듈화 조성물 및 모듈화 방법
US20040072262A1 (en) 2002-10-11 2004-04-15 Montero-Julian Felix A. Methods and systems for detecting MHC class I binding peptides
CA2541241A1 (en) * 2003-08-26 2005-03-03 Danmarks Tekniske Universitet A continuous process for the assembly of macromolecular substances and the subsequent capture and isolation of a macromolecular assembly, and a system suitable for the process
JP2007536522A (ja) * 2004-05-07 2007-12-13 ベックマン コールター インコーポレーティッド Ｃｔｌの媒介による抗原提示細胞の溶解を検出するためのｍｈｃ架橋系
US7678379B2 (en) 2004-06-17 2010-03-16 Beckman Coulter, Inc. Mycobacterium tuberculosis epitopes and methods of use thereof
AU2005321017B2 (en) 2004-12-28 2011-02-24 Innate Pharma S.A. Monoclonal antibodies against NKG2A
JP5368301B2 (ja) * 2006-06-22 2013-12-18 ノボ・ノルデイスク・エー／エス 可溶性ヘテロ二量体レセプター及びその使用
CN101484471B (zh) 2006-06-30 2013-11-06 诺沃-诺迪斯克有限公司 抗-nkg2a抗体及其用途
EP2628753A1 (en) 2008-01-24 2013-08-21 Novo Nordisk A/S Humanized anti-human NKG2A monoclonal antibody
KR102047248B1 (ko) 2011-06-17 2019-11-21 노보 노르디스크 에이/에스 침식성 세포의 선택적 제거
EP2893003B1 (en) 2012-09-04 2021-03-31 Inven2 AS Selective and controlled expansion of educated nk cells
HK1217968A1 (zh) * 2013-03-12 2017-01-27 桑格摩生物科学股份有限公司 用於hla的修饰的方法和组合物
EP2970426B1 (en) 2013-03-15 2019-08-28 Michael C. Milone Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
US10287354B2 (en) 2013-12-20 2019-05-14 Novartis Ag Regulatable chimeric antigen receptor
US20170081411A1 (en) * 2014-03-15 2017-03-23 Novartis Ag Regulatable chimeric antigen receptor
US10857219B2 (en) * 2014-03-28 2020-12-08 The Board Of Regents Of The University Of Oklahoma Compositions comprising soluble HLA/M. tuberculosis-specific ligand complexes and methods of production and use thereof
AU2015259877B2 (en) 2014-05-15 2021-02-25 National University Of Singapore Modified natural killer cells and uses thereof
SMT202000562T1 (it) 2014-09-16 2020-11-10 Innate Pharma Neutralizzazionne delle vie inibitorie nei linfociti
CA2959463A1 (en) 2014-09-16 2016-03-24 Innate Pharma Treatment regimens using anti-nkg2a antibodies
KR20250067191A (ko) 2014-09-17 2025-05-14 노파르티스 아게 입양 면역요법을 위한 키메라 수용체에 의한 세포독성 세포의 표적화
EP3209687A1 (en) 2014-10-23 2017-08-30 Innate Pharma Treatment of cancers using anti-nkg2a agents
CA3012055A1 (en) 2016-01-21 2017-07-27 Innate Pharma Neutralization of inhibitory pathways in lymphocytes
EP3573997A4 (en) * 2017-01-24 2020-12-09 Abexxa Biologics, Inc. METHODS AND COMPOSITIONS INTENDED TO TARGE A COMPLEX INCLUDING A NON-CLASSIC HLA-I AND A NEO-ANTIGEN IN THE TREATMENT OF CANCER
MX2019011570A (es) 2017-03-27 2019-11-18 Nat Univ Singapore Lineas celulares estimuladoras para expansion y activacion ex vivo de celulas asesinas naturales.
KR102660336B1 (ko) 2017-03-27 2024-04-26 내셔널 유니버시티 오브 싱가포르 절단된 nkg2d 키메라 수용체 및 자연 살해 세포 면역요법에서의 그의 용도
AU2019219454A1 (en) * 2018-02-09 2020-08-27 National University Of Singapore Activating chimeric receptors and uses thereof in natural killer cell immunotherapy
WO2019165307A1 (en) * 2018-02-23 2019-08-29 Abexxa Biologics, Inc. Combination cancer therapy with anti-cancer agents and antibodies targeting a complex comprising non-classical hla-i and neoantigen
US11464840B2 (en) 2018-02-26 2022-10-11 Swey-Shen Chen Universal non-classical MHC I vaccines: HLA-E-restricted antigenic peptides as universal vaccines to treat allergy, inflammation, autoimmune and infectious diseases, and cancers
EA202092147A1 (ru) 2018-03-13 2021-03-04 Иннейт Фарма Лечение рака головы и шеи
EP3539552A1 (en) * 2018-03-16 2019-09-18 Deutsches Rheuma-Forschungszentrum Berlin Activation and expansion of nkg2c+ nk cells
CN112055717B (zh) 2018-04-02 2024-04-26 新加坡国立大学 用在免疫细胞中表达的膜结合抗细胞因子非信号传导粘合剂中和人细胞因子
EP3844186A4 (en) 2018-08-29 2022-08-17 National University of Singapore METHOD OF SPECIFIC STIMULATION OF SURVIVAL AND EXPANSION OF GENETICALLY MODIFIED IMMUNE CELLS
US11274150B2 (en) 2018-11-16 2022-03-15 Bristol-Myers Squibb Company Anti-human natural killer cell inhibitory receptor group 2A protein (NKG2A) antibodies
US12590148B2 (en) 2018-11-26 2026-03-31 Nkarta, Inc. Methods for the simultaneous expansion of multiple immune cell types, related compositions and uses of same in cancer immunotherapy
KR102943217B1 (ko) 2018-12-02 2026-03-25 페이트 세러퓨틱스, 인코포레이티드 향상된 iPSC 유래 효과기 세포를 사용한 면역요법
AU2020232691B2 (en) 2019-03-05 2023-06-29 Nkarta, Inc. CD19-directed chimeric antigen receptors and uses thereof in immunotherapy
GB201909509D0 (en) * 2019-07-02 2019-08-14 Immunocore Ltd Peptide-MHC complexes
WO2022072508A1 (en) 2020-09-30 2022-04-07 Dren Bio, Inc. Anti-cd94 antibodies and methods of use thereof
CA3229447A1 (en) * 2021-08-20 2023-02-23 Duke University Antibodies that target hla-e-host peptide complexes and uses thereof
CN120019146A (zh) * 2022-08-11 2025-05-16 宾夕法尼亚大学理事会 通用t细胞和组合物及它们的使用方法
WO2024206190A1 (en) * 2023-03-24 2024-10-03 Duke University Antibodies that target hla-e-host peptide complexes and uses thereof
WO2026016730A1 (zh) * 2024-07-17 2026-01-22 广州瑞风生物科技股份有限公司 一种突变hla-e重链、hla-e三聚体及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03112486A (ja) 1989-09-22 1991-05-14 Olympus Optical Co Ltd Ｈｌａ―ｂ３５遺伝子およびｄｎａプローブ並びに形質転換細胞
JPH03112487A (ja) 1989-09-22 1991-05-14 Olympus Optical Co Ltd ＨＬＡ―Ｂｗ５３遺伝子およびＤＮＡプローブ並びに形質転換細胞
JPH03112485A (ja) 1989-09-22 1991-05-14 Olympus Optical Co Ltd Ｈｌａ―ｃ遺伝子およびｄｎａプローブ並びに形質転換細胞
GB9725764D0 (en) * 1997-12-04 1998-02-04 Isis Innovation HLA-E binding

Also Published As

Publication number Publication date
JP2013081478A (ja) 2013-05-09
EP1036327B1 (en) 2009-07-29
JP2009106299A (ja) 2009-05-21
EP1036327A2 (en) 2000-09-20
EP2144065A1 (en) 2010-01-13
US20150361180A1 (en) 2015-12-17
ATE438096T1 (de) 2009-08-15
US20080274475A1 (en) 2008-11-06
DE69841020D1 (de) 2009-09-10
JP2010024233A (ja) 2010-02-04
WO1999028748A2 (en) 1999-06-10
US7410767B1 (en) 2008-08-12
WO1999028748A3 (en) 1999-12-23
JP5268828B2 (ja) 2013-08-21
JP4437160B2 (ja) 2010-03-24
JP2002513541A (ja) 2002-05-14
JP4336451B2 (ja) 2009-09-30

Similar Documents

Publication Publication Date Title
GB9725764D0 (en) HLA-E binding
NZ312327A (en) Controlling hemipteran insect pests with bacillus thuringiensis
ATE14021T1 (de) Verwendung von in wasser dispergierbaren polyisocyanat-zubereitungen als zusatzmittel fuer waessrige klebstoffe.
AU2795292A (en) Synthetic dna sequence having enhanced insecticidal activity in maize
NZ333128A (en) Engineered human DNase I with DNA hydrolytic activity at least 50 percent greater than native human DNase I
AU3166993A (en) Insulators for use in railway rail-fastening assemblies
WO1988002763A3 (en) Nucleating system for polyamides
EA199900475A1 (ru) Получение растительных гелей
AU5763598A (en) Injection device
IL113315A (en) Insecticidal fertilizer mixtures
ES2157164B1 (es) Un aparato,un procedimiento y un sistema para recibir informacion,un aparato para enviar informacion a un terminal de informacion portatil,un procedimiento de envio de informacion desde un aparato a un terminal de informacion portatil y un sistema para enviar y recibir informacio
SI1082373T1 (en) Substance system
EA199800867A1 (ru) Соединения тетрагидробетакарболина
DE3865418D1 (de) Antioxidanz-produkte.
GR3032393T3 (en) Deoxygenation of an oil product with a laccase
AU4088097A (en) Substituted 1,2,3,4-tetrahydro-2-dibenzofuranamines and 2-aminocyclohepta(b)benzofurans
ES2113328A1 (es) Articulo de recubrimiento para camas y analogos, y procedimiento para su confeccion.
HU9601653D0 (en) Method of identifying substances with a potential herbicidal or growth-regulatory action by means of vegetable transporter proteins, use of such transporter proteins for this purpose, and substances with a herbicidal or growth-regulatory action identified
AU6505898A (en) Sperm extender comprising native phosphocaseinate or beta-lactoglobulin, method for preparing same and uses
AU3384495A (en) Or-1 on orphan receptor belonging to the nuclear receptor family
MX9804043A (es) Composiciones parasiticidas a base de polisiloxanos ciclicos.
GR3020005T3 (en) Method and device for harvesting useful plants.
HU9602129D0 (en) Condensation and addition polymers with n,n'-bridged bis-tetramethylpiperidinyloxy groups
WO1998057986A3 (en) Human preprotachykinin b
AU1720497A (en) Use of primers for universal fingerprint analysis

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)